cyrilzakka/clinical-trials huggingface dataset:
Use of Cone Beam Kilovoltage Imaging in Patients Receiving Radiation Therapy for Head and Neck Cancer

To evaluate the use of cone beam computed tomography in treating head and neck to hopefully reduce side effects

The general purpose of this study is to evaluate Kilovoltage (kv) Imaging, specifically the Cone-beam CT (CBCT) scan device, to assess the accuracy of radiation therapy treatment delivery for patients with head and neck neoplasms

Eligibility Criteria:
Inclusion Criteria:

* any patient receiving radiation therapy for a head and neck tumor assigned to the new Elekta Synergy Linare Accelerator

Exclusion Criteria:

* NA
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3

The purpose of this study is to compare the clinical efficacy of the buprenorphine/naloxone combination tablet to methadone for opioid maintenance treatment.

S/A brief "Summary for the Public"

Eligibility Criteria:
Inclusion Criteria:

Individuals must be at least 18 years of age, currently opioid dependent and meet FDA criteria for narcotic maintenance treatment. Co-morbid substance abuse or dependence disorders may also be present. Individuals must be healthy despite drug dependency.

Exclusion Criteria:

Individuals with evidence of an active Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.
Nordic Walking and Chronic Low Back Pain

This is a randimized clinical trial comparing the effect of supervised Nordic walking versus unsupervised Nordic walking versus advice to stay active


Eligibility Criteria:
Inclusion Criteria:

* Finished treatment at secondary sector specialist spinal unit
* Able to understand and read Danish

Exclusion Criteria:

* Co-morbidity preventing patient from completing Nordic walking program
* Pain \<3 on 11 point box scale
* Unable to perform Watt Max Cykel Test
Virosensor -Based Real-time Diagnosis of Enterovirus 71 and Influenza Virus

To develop a real-time diagnostic technique with Virosensor for Enterovirus 71 and Influenza Virus detection, the investigators conduct a prospective clinical study. In comparison with results from direct sequencing of Enterovirus 71 and Influenza Virus, the investigators evaluate the performance of virosensor , including reproducibility, sensitivity, specificity, and cross-reaction. The potential factors which may interfere with the results would be investigated. With such technique, the investigators hope to make early diagnosis and give Enterovirus 71 and Influenza Virus patients early treatment to reduce the complications and case-fatality rate.

1. Sample acquirement： At National Taiwan University Hospital in Taiwan, we will enroll patients who have influenza-like illness or enterovirus infection . We will take three throat swabs for each patient: one for viral isolation, one for RT-PCR and the last for the Virosensor - based real-time diagnosis.
2. Virosensor diagnosis： Virosensor (structural chip-based optosensing virus probing system), which is for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-influenza-virus (or anti-Enterovirus 71-virus) and its influenza virus antigen (or Enterovirus 71 antigen) present in patients'and normal samples.
3. Gold standard： viral isolation and RT-PCR

Eligibility Criteria:
Inclusion Criteria:

* The patients with confirmed or suspected infection.
* The healthy person without disease.

Exclusion Criteria:

* None
Bioavailability and Mucosal Bioactivity of Avmacol® in Healthy Volunteers

Avmacol is an over-the-counter dietary supplement containing broccoli seed and sprout extracts in tablet form, hypothesized to activate protective cellular pathways including detoxication. In this study, healthy volunteers will take 3 days of Avmacol in order to evaluate both bioavailability and its bioactivity in cheek cells.

Avmacol is an over-the counter dietary supplement containing broccoli seed and sprout extracts in tablet form. Natural plant substances within Avmacol, called phytochemicals, are hypothesized to stimulate the body's own defense mechanisms against toxic substances commonly encountered in the environment, such as air pollution and tobacco smoke. The purpose of this study is twofold: 1) to assess the protective effects of Avmacol on the mucosa (cheek cells) of healthy volunteers, and 2) to assess the collection of cheek cells by scraping, as a less invasive method of studying drug effects in the body compared to drawing blood or a tissue biopsy. Ultimately, these results will be used to design a larger study of Avmacol in patients with tobacco-related head and neck cancer. Avmacol will be studied as a way to possibly prevent a second cancer from developing in these patients.

Eligibility Criteria:
Inclusion Criteria:

1. Age ≥ 18 years.
2. Members of all racial and ethnic groups are eligible.
3. Smoking and non-smoking people are eligible. The tobacco use assessment form must be completed following consent and registration.
4. No chronic use of steroids
5. Karnofsky Performance Scale ≥90%
6. Able to provide written, informed consent
7. For women of child-bearing potential (WOCBP), a negative urine pregnancy test must be documented within 7 days prior to the first study intervention
8. Willing to avoid cruciferous vegetables during the study interventions
9. Willing to avoid grapefruit or grapefruit juice 48 hours prior to or during the study
10. Willing to avoid daily vitamins and anti-inflammatory medications prior to and during the study
11. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for the duration of study participation.
12. Willing and able to perform self-collection of buccal cells as stated in the instruction manual

Exclusion Criteria:

1. No current or former diagnosis of cancer, with the exception of: carcinoma-in-situ of breast or cervix; non-melanomatous skin cancer; T1-2, N0, M0 differentiated thyroid carcinoma; superficial bladder cancer; T1a or T1b prostate cancer comprising \< 5% of resected tissue with normal prostate specific antigen (PSA) since resection
2. No use of chronic prescribed medications which are potent inducers or inhibitors of CYP3A4
3. Chronic use anticoagulation
Lifemel Honey to Reduce Leucopenia During Chemotherapy

This study will include 60 patients with early breast cancer referred to receive adjuvant chemotherapy with AC ( adriamycin- cyclophosphamide) or CAF ( adriamycin- cyclophosphamide- 5- fluorouracil ) combinations. These patients will receive every day one spoon of Lifemel honey or regular honey ( double blind)- during the adjuvant chemotherapy .Every week a WBC count will be performed in order to record the influence of Lifemel on myelotoxicity.


Eligibility Criteria:
Inclusion Criteria:

* breast cancer patient treated with adjuvant chemotherapy
* PS = 2 or less

Exclusion Criteria:

* none
HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry

The purpose of the HF2 (Hemodynamic Frontiers in Heart Failure) registry is to collect relevant patient-level demographic, clinical, laboratory, and hemodynamic data from patients implanted with pulmonary artery pressure sensor at participating centers to advance scientific knowledge about ambulatory hemodynamics monitoring and HF (Heart Failure) therapies. The data collected will be used for retrospective studies, quality improvement, identifying research cohorts, and member-initiated research.

Longitudinal, multi-center, and non-interventional registry. Patients will be identified as eligible for pulmonary artery pressure sensor implant by a heart failure cardiologist from the heart failure clinic. They will consent for device implant and procedure (right heart catheterization) per standard of care. Patients may also consent to the registry participation, which is optional. They will be informed that the registry intends to gather data and that they may be approached in the future for additional research based on their data and clinical situation. Additionally, patients who underwent pulmonary artery pressure sensor implantation from January 1, 2019, will be identified and consent will be obtained for registry participation, which is optional.

Eligibility Criteria:
Inclusion Criteria:

1. All patients would have been or will be implanted per indications from FDA approval/CHAMPION trial. These would be patients with NYHA (New York Heart Association) Class III heart failure who had a prior hospitalization.
2. Patients who meet the expanded FDA indication (BNP elevation without hospitalization or NYHA class II).

Exclusion Criteria:

1. Patients less than 18 years of age.
2. Pregnant women at the scheduled time of PA pressure sensor implant.
3. Patients unable or unwilling to have continuity of care in the heart failure clinic.
Retrospective Follow-up Study After Periacetabular Osteotomy in Adults

This is a retrospective study assessing pre- and postoperative radiographic indices of hip dysplasia in order to identify factors predicting failure following Periacetabular Osteotomy (PAO).

Even though the PAO is applied worldwide and is the preferred joint preserving treatment some issues remains unclear and controversial. One is the exact indication for surgery and risk factors for early failure of the procedure. The is a retrospective cohort study assessing pre- and postoperative radiographic indices of hip dysplasia in order to identify factors predicting failure following PAO. The minimum duration of follow-up is 2 years. Failure following PAO is defined by a WOMAC pain score \> 10 or the insertion of a total hip arthroplasty.

Eligibility Criteria:
Inclusion Criteria:

* PAO from 1999-2007
Investigation of Ferritin in Critically Ill Patients With Hemophagocytic Lymphohistiocytosis

Retrospective analysis of ferritin, outcome and HLH-criteria in critically ill patients.

The study is a retrospective register study of critically ill patients from Charité - Universitätsmedizin Berlin during 2000 and 2016 that had at least one measurement of plasma ferritin. Outcome, underlying diagnoses and HLH-2004 criteria (Henter JI et al. 2007) will be analyzed and the HScore of these patients will be calculated (Fardet L et al. 2014). All recorded data of the specific admission term in ICU will be used for the analysis. No follow-up of the patients after discharge will be performed in this study. The study does not involve any randomization or any drug testing.

Update 2019: We expanded our database for the years until 2018 and also for the surgical and medical ICUs of the Charité - Universitätsmedizin Berlin (from 256 to 2623 patients).

Update 2022: A systematic literature search will be performed to find suitable validation cohorts for multicenter validation of optimized HLH diagnostic criteria, which are calculated based on our data (new secondary endpoint).

Eligibility Criteria:
Inclusion Criteria:

* male and female patients
* at least one measurement of plasma ferritin

Exclusion Criteria:

-age below 18 years
Yoga Versus Health Education for the Treatment of Persistent Fatigue in Patients With Post COVID-19 Syndrome

Evaluation of the short- and medium-term effect of a yoga intervention in addition to routine care compared to health education in addition to routine care on fatigue in patients with post covid syndrome.


Eligibility Criteria:
Inclusion Criteria:

* Confirmed COVID-19 diagnosis
* Follow-up symptoms of ≥ 12 weeks
* Persistent fatigue (scores ≥4 on the binomial Chalder Fatigue Scale).
* Self-assessment that fatigue was a consequence of COVID-19 disease
* Age 18-65 years

Exclusion Criteria:

* Chronic medical conditions or regular use of medications associated with fatigue
* Indication of health cause of fatigue other than post-COVID.
* Indication of other factors as the main cause of fatigue
* Physical limitations that do not allow participation in the yoga intervention
* Pregnancy, breastfeeding
* Concurrent participation in other clinical trials
* Current yoga practice
The Rechallenge of ADCs in MBC Patients

To investigate the efficacy and safety of ADC rechallenge


Eligibility Criteria:
Inclusion Criteria:

* age \> 18 years old.
* Diagnosed with Metastatic Breast Cancer.
* Patients with prior exposure to ADC (either in the adjuvant setting or metastatic disease are allowed).
* Patients plan to or have received ADCs for the second or more time.
* Complete medical history was available.

Exclusion Criteria:

* Medical history was incomplete
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer

The purpose of this study is to evaluate the safety and time to progression of HLA-A\*0201 restricted epitope peptides VEGFR1 and VEGFR2 emulsified with Montanide ISA 51 in combination with Tegafur/Uracil/Folinate chemotherapy.

VEGF receptor 1 and 2 are essential targets to tumor angiogenesis, and we identified that peptides derived from these receptors significantly induce the effective tumor specific CTL response in vitro and vivo. According to these findings, in this trial, we evaluate the safety, clinical and immunological response of those peptides. Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection. The patients will also receive oral chemotherapy (Tegafur/Uracil/Folinate) simultaneously. Repeated cycles of the vaccine and the chemotherapy will be administered until patients develop progressive disease or unacceptable toxicity, whichever occurs first. In the phase I study, we evaluate the safety and tolerability of these peptide vaccine. In the following phase II study, we evaluate the immunological and clinical response of this vaccine therapy.

Eligibility Criteria:
Inclusion Criteria:

* Advanced or recurrent colorectal cancer
* Resistant against chemotherapy including CPT-11, l-OHP、+/- 5-FU +/- bevacizumab or difficult to continue the chemotherapy due to intolerable side effect(s)
* ECOG performance status 0-2
* Life expectancy \> 3 months
* HLA-A\*0201
* Laboratory values as follows

  * 2000/mm3\<WBC\<15000/mm3
  * Platelet count\>100000/mm3
  * Bilirubin \< 3.0mg/dl
  * Asparate transaminase \< 150IU/L
  * Alanine transaminase \< 150IU/L
  * Creatinine \< 3.0mg/dl
* Able to receive oral Tegafur/Uracil/Folinate therapy
* Able and willing to give valid written informed consent

Exclusion Criteria:

* Pregnancy(woman of childbearing potential:Refusal or inability to use effective means of contraception)
* Breastfeeding
* Active or uncontrolled infection
* Unhealed external wound
* Concurrent treatment with steroids or immunosuppressing agent
* Prior chemotherapy,radiation therapy, or immunotherapy within 4 weeks
* Uncontrolled brain and/or intraspinal lesion(s)
* History of allergy to Tegafur, Uracil, and/or Folinate
* Decision of unsuitableness by principal investigator or physician-in-charge
Evaluation of the Bonfils Fiberscope for Predicted Difficult Intubation in Awake Patients With Ear, Nose, and Throat (ENT) Cancer (INVIBO)

The Bonfils intubation fiberscope (BF), a rigid medical device with a curved tip, is exclusively used in anesthesiology for orotracheal intubation (OTI). The objective of the study was to evaluate the feasibility and the tolerance of an intubation procedure realized by means of the BF (BFI) in awake adult patients with predicted difficult intubation (PDI), in the context of ENT cancer surgery.

The intubation is performed under local anesthesia (either nasal, oral, or intercricothyroidal) and sedation using Remifentanyl (AIVOC) with spontaneous ventilation. The primary endpoint is the rate of BFI meeting quality requirements: the procedure must be both successful (≤ 2 attempts and duration \< 180 sec) and well tolerated (Fahey score \< 2). The secondary endpoints include the difficulties met by the operator during the BFI and patient's perception of the intubation procedure, evaluated in the recovery room and 7 days after the intervention. Sample size is calculated using a one-stage Fleming design with p0=80%, p1=95%, alpha=5% and 80% power, for a total of 32 evaluable patients.


Eligibility Criteria:
Inclusion Criteria:

* Male or female patients aged ≥ 18 years
* Requiring a surgical intervention for an ENT carcinoma
* Presenting with a PDI defined either as an Arne Score \> 11, or a previous history of DI or by the surgeon's judgment.
* Able to understand, read and write French
* Signed, written informed consent

Exclusion Criteria:

* Impossible mask ventilation
* Patient with a laryngeal stridor indicative of upper airway stenosis
* Patient requiring an intubation by nasal route
* Glasgow score \< 12
* BMI \> 35
* Pregnant or lactating women
* Documented history of cognitive or psychiatric disorders
* Difficult follow-up
Study of the Anatomical and Functional Recovery and Quality of Life of Patients Undergoing Corneal Transplantation

Evaluate the well-being of patients and clinicl outcomes of the cornea after transplantation

The study aims to evaluate patients affected by corneal diseases who will undergo corneal transplantation.

The evaluation will be carried out pre and post transplantation to evaluate the clinical outcome of the patients and the quality of life and functional anatomical recovery.

Eligibility Criteria:
Inclusion Criteria:

* be eighteen years old
* diagnosis of corneal disease with prescription of surgical treatment of corneal transplantation
* sign the informed consent

Exclusion Criteria:

* no exclusion criteria
ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)

Diabetic and nondiabetic patients will be evaluated if they had a first diagnosis of non-valvular atrial fibrillation and in therapy with non-vitamin K oral anticoagulants and with vitamin K oral anticoagulants.

Parameters evaluated:

* anthropometric indices
* glycated haemoglobin, basal and postprandial glycemia
* lipid profile
* small and dense LDL; oxidized LDL
* I troponin
* red and white cells count; platelets count
* creatinin, transaminases, iron
* fibrinogen, D-dimer, anti-thrombin III
* Hs-CRP, metalloproteinases 2 and 9
* incidence of bleeding

Eligibility Criteria:
Inclusion Criteria:

* non-valvular atrial fibrillation
* nondiabetic patients
* type 1 and 2 diabetic patients

Exclusion Criteria:

* patients with cancer
* patients with chronic inflammation diseases
Cervical Stabilization Exercises on Respiratory Strength in Chronic Neck Pain

This project was a Randomized control trial conducted to check the effects of Cervical Stabilization Exercises on Respiratory Strength in Chronic Neck Pain Patients with Forward Head Posture, duration of study was of 6 months, convenient sampling was done, subject following eligibility criteria from Jinnah Hospital Lahore, were randomly allocated in two groups via lottery method, baseline assessment was done, Group A participants were given baseline treatment protocol for 4 weeks which included 3 sessions per week. Heating Pad applied for 15 min and TENS (Transcutaneous Electric Nerve Stimulation) for 10 min. After that Cervical isometric exercises performed in sitting (10sec hold, 10 to 15 reps). Group B was experimental group and participants were given baseline treatment in addition to Cervical Stabilization exercises for 4 weeks which included 3 sessions per week. The baseline measurement was taken on day one for Numeric Pain Rating Scale (NRPS) and Neck Disability Index (NDI). Forward head posture assessed by measuring Cranio Vertebral Angle (CVA). Respiratory muscle strengths measured by Spirometer and SBC (single breath count). All the measurements repeated at the end of fourth week. Data was analyzed by using SPSS version 20.

Extensive usage of electronic gadgets in today's life leads to the musculoskeletal problems among which neck pain is the most common problem reported to physicians, orthopedics and physical therapists. Even before reporting to clinics there is long history of using over the counter pain killers. Pain avoidance behaviors let the cervical spine stiff so much that a clinician help is sought. There is huge literature regarding the management of chronic neck pain and yet after the decades of research there are gaps in treatment options. In modern age of health care, it is common goal of every healthcare to make patient self-sufficient as early as possible. The self-care models have tremendous advantages. The current study has compared the effects of cervical stabilization exercises and isometric exercises. The current study was novel in a way that there is limited literature about treating Chronic Neck Pain Patients with effects of physiotherapy on respiratory strength in improving forward head posture. All the methods were employed to see if they improve ranges along with accompanying pain and disability.

Eligibility Criteria:
Inclusion Criteria:

* Patients with chronic neck pain for more than 3 months.
* Mild neck disability (NDI score 5-15)

Exclusion Criteria:

* Neck pain secondary to trauma
* Deformities of thoracic region or vertebral column
* History of any thoracic or vertebral column surgery.
* History of smoking
* Patients with any other serious pathology/red flags
Pain and Stress Assessment and ROP Screening

The study will measure the effects of eye exams on markers of stress in the urine. In addition, measurements will be taken to show the effects of stress on brain activity, O2 sats, and blood flow.


Eligibility Criteria:
Inclusion Criteria:

* Premature infants between 24 -32 weeks of gestational age

Exclusion Criteria:

* Infants scheduled for laser eye surgery on the day of the examination
* Infants with intraventricular hemorrhage ≥ grade 3 (Papile classification) diagnosed by head ultrasound
* Infants receiving the following medications: morphine, fentanyl, methadone, midazolam, lorazepam, muscle relaxants, phenobarbital, phenytoin, levetiracetam
* Renal injury defined with plasma creatinine \> 1.5 mg/dL
* Severe cyanotic congenital heart disease
* Unstable respiratory distress (hypoxemia PaO2 \< 50 mm Hg or SpO2 \< 90%)